Skip to Content

Horizon Therapeutics PLC HZNP Stock Quote

| Rating as of


Last close prices updated as of Jan 27, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 111.25
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Mid Growth
  • Day Range 110.62  –  111.34
  • Year Range 57.84  –  117.49
  • Market Cap 25.2669 Bil
  • Volume / Avg 4.6 Mil /  4.2 Mil
  • Price / Sales 7.10
  • Price / Book 5.05
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis HZNP

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics HZNP

Company Profile HZNP

Business Description

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company has two reportable segments: orphan and inflammation. Orphan segment consists of medicines such as TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, UPLIZNA, BUPHENYL, and QUINSAIR. Inflammation segment consists of PENNSAID 2%, DUEXIS, RAYOS, and VIMOVO. It generates the vast majority of its revenue from the United States.

70 St. Stephen’s Green
Dublin 2, D02 E2X4, IRL
Industry Drug Manufacturers - General
Employees 2,095

Related Articles HZNP

FAQs for Horizon Therapeutics PLC Stock

No. HZNP does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

HZNP’s market cap is 25.27 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

HZNP’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

HZNP’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare HZNP’s historical performance against its industry peers and the overall market.